Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 75

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 75
---
 in each case subject to certain exceptions.
The Companies Law imposes further restrictions on our ability to declare and pay dividends.

<div align='center'>49</div>

If we do raise additional capital, shareholders may be subject to dilution.

If we issue additional shares
of our Ordinary Shares or other equity securities convertible into share capital to fund operations, develop new products, accelerate
other strategies, make acquisitions or support other activities, the ownership interests of investors in this offering will be diluted.
Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond
our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional
capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other
preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment
obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term
but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or
grant licenses on terms unfavorable to us.

Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control.

After this offering, our
directors, officers, holders of more than 5% of our outstanding shares and their respective affiliates will beneficially own shares representing
approximately 59.2% of our outstanding Ordinary Shares, assuming no exercise of the Representative’s option to purchase additional
shares and additional warrants without giving effect to any shares that certain of these holders may make through our directed share
program or otherwise. As a result, these shareholders, if they act together, will be able to influence our management and affairs and
all matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions. This
concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market
price of our Ordinary Shares.

The